Skip to main content
. 2016 Jan 10;35(13):2195–2205. doi: 10.1002/sim.6853

Table 3.

Results from application to CHARM‐Added and CHARM‐Alternative. H R GL, H R JFM1: hazard ratios from Ghosh and Lin and joint frailty models respectively for recurrent heart failure hospitalisations. H R CPH, H R JFM2: hazard ratios from Cox proportional‐hazards and joint frailty models respectively for time to CV death. θ, α: frailty variance and frailty exponent respectively.

CHARM‐Added CHARM‐Alternative
Estimate 95% CI P‐value Estimate 95% CI P‐value
H R GL 0.683 0.57‐0.82 <0.0001 0.687 0.55‐0.86 0.0008
H R JFM1 0.650 0.53‐0.80 <0.0001 0.608 0.49‐0.76 <0.0001
H R CPH 0.842 0.72‐0.98 0.029 0.847 0.71‐1.02 0.072
H R JFM2 0.839 0.70‐1.01 0.065 0.851 0.68‐1.07 0.172
θ (SE) 3.751 (0.208) 3.452 (0.207)
α (SE) 0.688 (0.054) 0.846 (0.069)

CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity.